CD11B+ B Cells in the Circulation Are Predominantly Clonotypic
| Patient (no.) . | % of CD11B+19+ B Cells That Are Clonotypic . |
|---|---|
| 1 | 72 |
| 6 | 78 |
| 11 | 73 |
| 13 | 87 |
| 14 | 93 |
| Mean ± SE | 81 ± 4 |
| Normal PBMC B cells (16) | <0.3% |
| Normal BM plasma cells (5) | <0.3% |
| Patient (no.) . | % of CD11B+19+ B Cells That Are Clonotypic . |
|---|---|
| 1 | 72 |
| 6 | 78 |
| 11 | 73 |
| 13 | 87 |
| 14 | 93 |
| Mean ± SE | 81 ± 4 |
| Normal PBMC B cells (16) | <0.3% |
| Normal BM plasma cells (5) | <0.3% |
Myeloma PBMC were stained with CD11B-PE and CD19-FITC as indicated in Materials and Methods. All CD11B+ PBMC coexpressed CD19. The CD11Bhi and CD19+ subset was sorted onto slides as previously described7 and used in in situ RT-PCR with patient-specific primers to CDR2 and CDR3. Every assay included tests with sorted B cells from 10 healthy normal donors and BM plasma cells from four healthy donors, from which no clonotypic transcripts were detectable. The CDR3 sequence for each of the patients is given below. The CDR3 primer sequences are given in bold.
1.TGTGCTCAC…AAACTTATCACTGGTTGGGACGGTAGTAGT…………TACTTTGACCAG.TGGGGC
6.TGTGCGAGG…GTCCCCATGAACTATGCTATAAGGGGAAACTTAGGT……TCCATTGACTAC.TGGGGC
11.TGTGCGCCA…GTTCTTGCCAACTGGTTT…………………CGCCCCTTTGACCAC.TGGGGC
13.TGTGCGACA…GATCAAGATGACTACGGTGACTACGGGACC……………TTTAACTCC.TGGGGC
14.TGTACGAGA…GTAAATCCTTTCTATGAAGGTAGTCGTTATCCCATA…TACTACTTTGGCTAC.TGGGGC